View Older Stories View More Recent Stories

Nov 17, 2021 09:32AM AbbVie (ABBV) Triple Data Could Be Pushed Back According to CT.gov - Analyst

Nov 17, 2021 09:15AM The US, Not EU Market is Bulk of Biogen (BIIB) Aduhelm's Value, lecanemab Offers Further Potential Upside - Analyst

Nov 5, 2021 08:54AM Pfizer's (PFE) COVID Pill Best in Class, Will Put Pressure on Merck (MRK) and Regeneron (REGN) - Analyst

Oct 29, 2021 09:04AM AddVie (ABBV) Continues to Deliver, Despite Concerns - Analyst

Oct 28, 2021 08:41AM CEO Departure Likely to Pressure Alnylam (ALNY) Stock, M&A Possibility Will Likely Fade - Analyst

Oct 26, 2021 10:55AM Too Early to Tell What Eli Lilly’s (LLY) Study Means for Biogen’s (BIIB) Aduhelm – Analyst

Oct 20, 2021 08:21AM Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst

Oct 18, 2021 12:59PM CRL is a Negative, but Omeros (OMER) Stock is Trading Far Below Fundamental Value - Analyst

Oct 18, 2021 12:09PM United Therapeutics’ (UTHR) Tyvaso’s CRL is a Second Chance for Mannkind (MNKD) Investors – Analyst

Oct 18, 2021 09:32AM Oyster’s (OYST) Tyrvaya is Meaningfully Differentiated, Can Reach $1B+ Peak Sales – Analyst

Oct 18, 2021 07:28AM Any Weakness in United Therapeutics' (UTHR) Stock is a Buying Opportunity - Analyst

Oct 14, 2021 09:18AM DarioHealth’s (DRIO) Health Plan Win is a Major Step Forward in B2B Transformation - Analyst

Oct 12, 2021 01:22PM Gavi’s Purchase of Additional Moderna’s (MRNA) mRNA-1273 Supply Supports Long-Term Outlook - Analyst

Oct 12, 2021 10:28AM Aerie Pharmaceuticals, Inc’s (AERI) Rhopressa is Particularly Well Positioned for Japan Entry - Analyst

Oct 12, 2021 10:13AM Berkeley Lights (BLI) Prelim Results Are Strong Start to Regain Investor's Confidence - Analyst

Oct 8, 2021 01:25PM ChemoCentryx (CCXI) Tavneos’s Label is Best Case Scenario Outcome; Drug Has Blockbuster Potential - Analyst

Oct 8, 2021 01:04PM No Material Readacross for Atara Biotherapeutics (ATRA) from Allogene’s (ALLO) Hold – Analyst

Oct 8, 2021 11:01AM Bicycle Therapeutics plc (BCYC) New Data Further Demonstrates Enormous Therapeutic Potential - Analyst

Oct 6, 2021 11:51AM Takeda's (TAK) Loss Could be Jazz's (JAZZ) Gain - Analyst

Oct 4, 2021 11:43AM Clear's (YOU) iPhone (AAPL) Integration Alleviates Competitive Concerns - Analyst

Oct 4, 2021 08:56AM Xenon's (XENE) X-Tole Data as Good as it Gets with Best-in-Category Efficacy - Analyst

Sep 14, 2021 10:22AM RedHill Biopharma’s (RDHL) Base Business and Pipeline Remain Undervalued - Analyst

Sep 13, 2021 12:46PM REGENXBIO Inc. (RGNX) Deal With Abbvie (ABBV) 'Validates Positive Outlook' - Analyst

Sep 10, 2021 08:30AM Iveric bio (ISEE): APLS Data As Good As Possible for Iveric, Buy Here - Analyst

Sep 9, 2021 07:26AM Humanigen Inc. (HGEN) 'Investment Thesis on Stock Remains Intact' Analyst

Aug 26, 2021 09:57AM Ascendis Pharma’s (Nasdaq: ASND) Now Approved SKYTROFA Seen as “best-in-class product” by Credit Suisse

Aug 25, 2021 01:09PM Moderna, Inc’s (MRNA) Vaccine’s FDA Approval Could Lead to Greater Market Share in Coming Years - Analyst

Aug 19, 2021 08:45AM Illumina (ILMN) Shares Poised for a Drop Following GRAIL Acquisition - Bloomberg

Aug 10, 2021 01:34PM Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst

Aug 9, 2021 01:33PM Axsome Therapeutics's (AXSM) AXS-05 Deficiencies Set Stage for Near-Term CRL - Analyst

Aug 4, 2021 09:47AM BeyondSpring's (BYSI) Plinabulin Data Represents Significant Advance, Patients Win 100%, $100 Price Target - Analyst

Aug 3, 2021 02:38PM Moderna, Inc’s (MRNA) mRNA-1345 Fast Track Designation is Encouraging; Peak Sales Up to $2.12B - Analyst

Aug 3, 2021 11:54AM Outlook Therapeutics, Inc. (OTLK) Phase 3 Data Supports Approval - Analyst

Aug 2, 2021 02:03PM Alkermes' (ALKS) Nemvaleukin Alfa Granted FDA Fast Track Designation

Aug 2, 2021 09:20AM AstraZeneca's (AZN) Just Approved Saphnelo has 'Blockbuster Potential', Peak Sales Underestimated - Analyst

Aug 2, 2021 08:20AM Autolus Therapeutics' (AUTL) Deal with MRNA - Broad Validation of the Platform - Analyst

Aug 2, 2021 07:05AM Myriad Genetics (MYGN) Launches First Breast Cancer Risk Assessment Test for Women of All Ancestries

Jul 28, 2021 02:56PM Optinose (OPTN) Full Year Target Not Only Achievable, But Likely Conservative - Analyst

Jul 27, 2021 11:37AM Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst

Jul 27, 2021 08:11AM Peak Sales Potential of Merck's (MRK) Keytruda is Underappreciated - Analyst

Jul 23, 2021 08:28AM Israel Says Pfizer (PFE) Vaccine Only 39% Effective in Preventing Delta Variant Infection

Jul 22, 2021 09:34AM Biogen (BIIB) Q2 Results: Only ~35% of Expected Sites Have Indicated Acceptance of Aduhelm - Analyst

Jul 21, 2021 10:51AM FDA's Clinical Hold Doesn't Affect Magenta Therapeutics' (MGTA) MGTA-117 Prospects - Analyst

Jul 21, 2021 10:26AM Calliditas Therapeutics AB (CALT) Gains on EU Licensing Deal

Jul 21, 2021 09:53AM 'Sunshine and Blue Skies' Ahead For Johnson & Johnson (JNJ) Following Strong Q2 Beat

Jul 20, 2021 11:16AM New Data Support MediWound's (MDWD) NexoBrid's Safety and Efficacy - Analyst

Jul 20, 2021 09:57AM Ardelyx's (ARDX) Shares Plunge as Tenapanor's Deficiencies Identified by FDA 'Take Approval Off the Table'

Jul 19, 2021 01:58PM Cytokinetics' (CYTK) Redwood-HCM Top-line Results 'Deliver on All Fronts' - Analyst

Jul 16, 2021 11:34AM What Negative Roxadustat FDA AdCom Vote Means for Fibrogen's (FGEN) Stock?

Jul 15, 2021 06:00PM Expert Panel Unanimously Decides Biogen's (BIIB) Aduhelm Offers no Patient Benefit

View More Recent Stories View Older Stories